<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053911</url>
  </required_header>
  <id_info>
    <org_study_id>PACS03</org_study_id>
    <secondary_id>FRE-FNCLCC-PACS-03/003</secondary_id>
    <secondary_id>EU-20237</secondary_id>
    <nct_id>NCT00053911</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer</brief_title>
  <official_title>Randomized And Multicentric Phase III Study Evaluating The Benefit By Using A Chemotherapy With FEC 100 And Docetaxel In Non Metastatic Breast Cancer Which Has Relapsed After A Conservative Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug, and giving them after surgery, may
      kill any remaining tumor cells following surgery. It is not yet known whether combination
      chemotherapy is more effective than observation in treating relapsed nonmetastatic breast
      cancer.

      PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy
      with that of observation in treating women who have undergone surgery for relapsed
      nonmetastatic breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the efficacy of adjuvant cyclophosphamide, epirubicin, and fluorouracil vs
           observation, in terms of disease-free 5-year survival, in women who have undergone
           resection for relapsed nonmetastatic breast cancer after initial conservative surgery.

        -  Compare the overall survival of women treated with these regimens.

        -  Determine the tolerance of these women to the chemotherapy regimen.

        -  Correlate prognostic factors of survival with efficacy of the chemotherapy regimen in
           these women.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
      menopausal status and participating center. Patients are randomized to 1 of 2 treatment arms.
      Study begins within 42 days after resection of recurrent disease.

        -  Arm I: Patients receive fluorouracil IV over 1 hour, epirubicin IV over 1 hour, and
           cyclophosphamide IV over 1 hour on day 1. Treatment repeats every 3 weeks for 3 courses
           in the absence of disease progression or unacceptable toxicity. Patients then receive
           docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks for 3 courses in the
           absence of disease progression or unacceptable toxicity.

        -  Arm II: Patients are examined on days 1 and 63.

      Patients who are hormone receptor positive also receive one of the following hormonal therapy
      regimens, depending on menopausal status:

        -  Oral tamoxifen daily for 5 years

        -  Oral tamoxifen daily for 5 years and oral luteinizing hormone-releasing hormone (LHRH)
           agonist therapy (e.g., goserelin) for 3 years

        -  Oral LHRH agonist therapy (e.g., goserelin) for 3 years

        -  Oral antiaromatase therapy (e.g., anastrozole) for 5 years Patients also undergo
           radiotherapy and may also undergo second complete resection.

      Patients are followed every 6 months for 5 years and then annually thereafter.

      PROJECTED ACCRUAL: A total of 370 patients (185 per treatment arm) will be accrued for this
      study within 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>November 2002</start_date>
  <primary_completion_date type="Actual">April 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of the disease free survival</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anastrozole</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>goserelin acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tamoxifen citrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the breast

               -  No contralateral breast cancer

          -  Local tumor recurrence more than 6 months after conservative surgery

          -  Complete or conservative resection of the recurrent tumor NOTE: Initial complete
             surgical resection not allowed

          -  No local inflammatory disease or disease that is not amenable to complete surgical
             resection

          -  No positive axillary lymph nodes

          -  No distant metastases, including subclavicular lymph nodes

          -  Hormone receptor status:

               -  Hormone receptor status known

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 65

        Sex

          -  Female

        Menopausal status

          -  Menopausal status known

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Neutrophil count at least 2,000/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic

          -  Bilirubin no greater than upper limit of normal (ULN)

          -  Transaminases no greater than 1.5 times ULN

          -  Alkaline phosphatase no greater than 2.5 times ULN

          -  No chronic hepatitis B

          -  No active hepatitis C

        Renal

          -  Not specified

        Cardiovascular

          -  Cardiac function normal by echocardiogram or isotopes

        Other

          -  No contraindications to anthracyclines such as any of the following:

               -  Prior doxorubicin over 300 mg/m^2

               -  Prior epirubicin over 600 mg/m^2

               -  Prior mitoxantrone over 90 mg/m^2

          -  No other invasive malignancy

          -  No chronic somatic or psychiatric condition that would preclude study participation

          -  No familial, social, geographic, or psychological reason that would preclude study
             participation

          -  Not pregnant

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  CA 153 no greater than 2 times ULN

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Patient Characteristics-Other

          -  No prior neoadjuvant chemotherapy

        Endocrine therapy

          -  No prior neoadjuvant hormonal therapy

        Radiotherapy

          -  No prior neoadjuvant radiotherapy

        Surgery

          -  See Disease Characteristics

          -  At least 41 days since prior surgery
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles Romieu, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <zip>81000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74011 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Sainte Catherine</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. Bourg En Bresse</name>
      <address>
        <city>Bourg En Bresse</city>
        <zip>01012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hopital A. Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier General</name>
      <address>
        <city>Brive</city>
        <zip>19101</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Compiegne</name>
      <address>
        <city>Compiegne</city>
        <zip>60321</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique du Petit Colmouilins</name>
      <address>
        <city>Harfleur</city>
        <zip>76700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre-Dame de Bon Secours</name>
      <address>
        <city>Metz</city>
        <zip>57038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.H. General Andre Boulloche</name>
      <address>
        <city>Montbeliard</city>
        <zip>25209</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mulhouse</name>
      <address>
        <city>Mulhouse</city>
        <zip>68051</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Rene Gauducheau</name>
      <address>
        <city>Nantes-Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint - Pierre</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Eugene Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Armoricaine De Radiologie</name>
      <address>
        <city>Saint Brieux</city>
        <zip>F-22015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polyclinique de L'Ormeau</name>
      <address>
        <city>Tarbes</city>
        <zip>65000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital J. Ducuing</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <last_update_submitted>December 14, 2014</last_update_submitted>
  <last_update_submitted_qc>December 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2014</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Goserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

